Sandy Smith
Director/Board Member presso CYTOKINETICS, INCORPORATED
Patrimonio netto: 957 212 $ in data 31/03/2024
Profilo
Sandford D.
Smith founded Global Biolink Partners in 2011, where he is working as Chairman from 2011.
Mr. Smith also currently works at Cytokinetics, Inc., as Independent Director from 2012 and Tullis Health Investors, Inc., as Operating Partner from 2013.
Mr. Smith also formerly worked at Repligen Corp., as President, Chief Executive Officer & Director from 1986 to 1996, ARIAD Pharmaceuticals, Inc., as Vice Chairman from 1991 to 2008, Aegerion Pharmaceuticals, Inc., as Chairman in 2016, Novelion Therapeutics, Inc., as Vice Chairman from 2016 to 2017, Apricus Biosciences, Inc., as Independent Director from 2014 to 2019, Nventa Biopharmaceuticals Corp., as Director from 2007 to 2009, BioBehavioral Diagnostics Co., as Director, Seneca Biopharma, Inc., as Independent Director from 2014 to 2020, Boston Philharmonic Orchestra, as Director, Akcea Therapeutics, Inc., as Independent Director from 2017 to 2020, Bristol Myers Squibb Co., as VP-Business Development & Strategic Planning from 1977 to 1986, Genzyme Corp., as President-International Group & Executive VP in 2011, The Brigham & Women's Hospital, Inc., as Trustee, Genzyme Therapeutics Ltd., as President from 1996 to 2011, and Genzyme International, as President.
Mr. Smith received his undergraduate degree from the University of Denver.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 29/02/2024 | 13 653 ( 0.01% ) | 957 212 $ | 31/03/2024 |
Posizioni attive di Sandy Smith
| Società | Posizione | Inizio |
|---|---|---|
| CYTOKINETICS, INCORPORATED | Director/Board Member | 05/03/2012 |
Tullis Health Investors, Inc.
 Tullis Health Investors, Inc. Investment ManagersFinance Tullis Health Investor Inc (Tullis Health) is a private equity and venture capital firm founded in 1986 by Jim Tullis. The firm is headquartered in Palm Beach, Florida. | Private Equity Investor | 01/01/2008 |
| Global Biolink Partners | Founder | 01/12/2011 |
Precedenti posizioni note di Sandy Smith
| Società | Posizione | Fine |
|---|---|---|
| AKCEA THERAPEUTICS, INC. | Director/Board Member | 12/10/2020 |
| PALISADE BIO, INC. | Director/Board Member | 26/03/2020 |
Apricus Biosciences, Inc.
 Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Director/Board Member | 24/01/2019 |
| NOVELION THERAPEUTICS INC. | Director/Board Member | 31/03/2017 |
| AEGERION PHARMACEUTICALS, INC. | Chief Executive Officer | 07/01/2016 |
Formazione di Sandy Smith
| University of Denver | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| REPLIGEN CORPORATION | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| Aziende private | 15 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Health Technology |
Nventa Biopharmaceuticals Corp.
 Nventa Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
BioBehavioral Diagnostics Co.
 BioBehavioral Diagnostics Co. Medical SpecialtiesHealth Technology BioBehavioral Diagnostics Co. manufactures and markets attention-deficit hyperactivity disorder systems. It develops and markets a proprietary platform technology to objectively measure specific behaviors that correlate with brain function and deficits in inhibitory control. The firm's product Quotient ADHD System measures impulsivity, hyperactivity and inattention as an aid in the assessment of ADHD and this system includes a data acquisition unit, a proprietary normative database, analytics and reports. The company was founded by Eric B. Gordon in 2006 and is headquartered in Westford, MA. | Health Technology |
Tullis Health Investors, Inc.
Tullis Health Investors, Inc. Investment ManagersFinance Tullis Health Investor Inc (Tullis Health) is a private equity and venture capital firm founded in 1986 by Jim Tullis. The firm is headquartered in Palm Beach, Florida. | Finance |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Seneca Biopharma, Inc.
 Seneca Biopharma, Inc. BiotechnologyHealth Technology Seneca Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD. | Health Technology |
Boston Philharmonic Orchestra
 Boston Philharmonic Orchestra Movies/EntertainmentConsumer Services Boston Philharmonic Orchestra is a semi-professional orchestra. The company was founded by Benjamin Zander in 1979 and is headquartered in Boston, MA. | Consumer Services |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
| Genzyme International | |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
| Global Biolink Partners |
- Borsa valori
- Insiders
- Sandy Smith
